201 related articles for article (PubMed ID: 25214642)
21. [Utility and prognostic value of PET/CT, bone marrow biopsy and aspirate for detection of bone marrow involvement in diffuse large B-cell lymphoma].
Jiang XY; Zou DM; Zhang YQ; Wang Z; Zhang W; Zhou DB; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):663-667. PubMed ID: 36709151
[No Abstract] [Full Text] [Related]
22. Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma.
Kim M; Ahn SY; Ahn JS; Song GY; Jung SH; Lee JJ; Kim HJ; Lee JH; Shin MG; Song SY; Yang DH
J Korean Med Sci; 2022 Jan; 37(1):e2. PubMed ID: 34981678
[TBL] [Abstract][Full Text] [Related]
23. Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
Chow A; Phillips M; Siew T; Cull G; Augustson B; Ward M; Joske D
Intern Med J; 2013 Aug; 43(8):932-9. PubMed ID: 23692386
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
25. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.
Khan AB; Barrington SF; Mikhaeel NG; Hunt AA; Cameron L; Morris T; Carr R
Blood; 2013 Jul; 122(1):61-7. PubMed ID: 23660958
[TBL] [Abstract][Full Text] [Related]
26. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate.
Paone G; Itti E; Haioun C; Gaulard P; Dupuis J; Lin C; Meignan M
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):745-50. PubMed ID: 19096842
[TBL] [Abstract][Full Text] [Related]
28. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
30. Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
Wolach O; Fraser A; Luchiansky M; Shapiro C; Radnay J; Shpilberg O; Lishner M; Lahav M
Hematol Oncol; 2015 Mar; 33(1):42-7. PubMed ID: 24470400
[TBL] [Abstract][Full Text] [Related]
31. Poor prognosis in patients with diffuse large B cell lymphomas with bone marrow involvement possessing chromosomal abnormalities, despite aggressive treatment.
Min GJ; Jeon YW; Park SS; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
Ann Hematol; 2020 Mar; 99(3):557-570. PubMed ID: 31989249
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP.
Shim H; Oh JI; Park SH; Jang S; Park CJ; Huh J; Suh C; Chi HS
J Clin Pathol; 2013 May; 66(5):420-5. PubMed ID: 23610041
[TBL] [Abstract][Full Text] [Related]
33. Staging DLBCL: bone marrow biopsy or PET-CT?
Avigdor A
Blood; 2013 Jul; 122(1):4-5. PubMed ID: 23828884
[TBL] [Abstract][Full Text] [Related]
34. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
36. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma.
Nols N; Mounier N; Bouazza S; Lhommel R; Costantini S; Vander Borght T; Vekemans MC; Sonet A; Bosly A; Michaux L; André M; Van Den Neste E
Leuk Lymphoma; 2014 Apr; 55(4):773-80. PubMed ID: 23927393
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of (18)F-FDG PET/CT after first-line treatment in patients with diffuse large B cell lymphoma].
Ying ZT; Wang XJ; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ping LY; Liu WP; Deng LJ; Zhang C; Yang Z; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):810-3. PubMed ID: 23384899
[TBL] [Abstract][Full Text] [Related]
38. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma.
Gallicchio R; Mansueto G; Simeon V; Nardelli A; Guariglia R; Capacchione D; Soscia E; Pedicini P; Gattozzi D; Musto P; Storto G
Eur J Haematol; 2014; 92(5):382-9. PubMed ID: 24428392
[TBL] [Abstract][Full Text] [Related]
39. Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy.
Adams HJ; Kwee TC; Lokhorst HM; Westerweel PE; Fijnheer R; Kersten MJ; Verkooijen HM; Stoker J; Nievelstein RA
J Magn Reson Imaging; 2014 Jun; 39(6):1394-400. PubMed ID: 24310955
[TBL] [Abstract][Full Text] [Related]
40. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.
Muslimani AA; Farag HL; Francis S; Spiro TP; Chaudhry AA; Chan VC; Taylor HC; Daw HA
Am J Clin Oncol; 2008 Oct; 31(5):409-12. PubMed ID: 18838874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
